SPARC Gene Expression Is Increased in Diabetes-Related Mesenteric Vascular Hypertrophy

Allen, 1990, Glomerular filtration rate in the streptozocin diabetic rat: The role of exchangeable sodium, vasoactive hormones and insulin therapy, Diabetes, 38, 1182, 10.2337/diab.39.10.1182 Brownlee, 1988, Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications: The pathogenesis and prevention of diabetic neuropathy and nephropathy, N. Engl. J. Med., 318, 1315, 10.1056/NEJM198805193182007 Bunag, 1973, Validation in awake rats of a tail-cuff method for measuring systolic pressure, J. Appl. Physiol., 34, 279, 10.1152/jappl.1973.34.2.279 Cao, 1998, Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action, J. Hypertens., 16, 793, 10.1097/00004872-199816060-00010 Chiquet-Ehrismann, 1991, Anti-adhesive molecules of the extracellular matrix, Curr. Opin. Cell. Biol., 3, 800, 10.1016/0955-0674(91)90053-2 Chomczynski, 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, Anal. Biochem., 162, 156, 10.1016/0003-2697(87)90021-2 Cooper, 1994, Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition, Diabetes, 43, 1221, 10.2337/diab.43.10.1221 Dodge, 1992, Cell–cell interactions in diabetic angiopathy, Diabetes Care., 15, 1168, 10.2337/diacare.15.9.1168 Duncan, 1994, Expression of the helix–loop–helix protein, Id, during branching morphogenesis in the kidney, Kidney Int., 46, 324, 10.1038/ki.1994.278 Dziadek, 1986, Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumour, Eur. J. Biochem., 161, 455, 10.1111/j.1432-1033.1986.tb10466.x Funk, 1991, The Ca2+-binding protein that modulates cell cycle progression in bovine aortic endothelial cells, Proc. Natl. Acad. Sci. USA, 88, 2648, 10.1073/pnas.88.7.2648 Gilbert, 1995, SPARC gene expression is reduced in early diabetes-related kidney growth, Kidney Int., 48, 1216, 10.1038/ki.1995.405 Griffin, 1991, Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism, Hypertension, 17, 626, 10.1161/01.HYP.17.5.626 Heagerty, 1993, Small artery structure in hypertension. Dual processes of remodeling and growth, Hypertension, 21, 391, 10.1161/01.HYP.21.4.391 Lane, 1992, Regulation of gene expression by SPARC during angiogenesis in vitro, J. Biol. Chem., 267, 16736, 10.1016/S0021-9258(18)42063-7 Lane, 1994, The biology of SPARC, a protein that modulates cell–matrix interactions, FASEB J., 8, 163, 10.1096/fasebj.8.2.8119487 Mayer, 1991, Calcium-dependent binding of basement membrane protein BM-40 (osteonectin, SPARC) to basement membrane collagen type IV, Eur. J. Biochem., 198, 141, 10.1111/j.1432-1033.1991.tb15996.x Monnier, 1992, Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia, Diabetes, 2, 36, 10.2337/diab.41.2.S36 Pichler, 1996, SPARC is expressed in renal interstitial fibrosis and in renal vascular injury, Kidney Int., 50, 1978, 10.1038/ki.1996.520 Porter, 1995, Distribution of SPARC in normal and neoplastic human tissue, J. Histochem. Cytochem., 43, 791, 10.1177/43.8.7622842 Raines, 1992, The extracellular glycoprotein SPARC interacts with platelet derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors, Proc. Natl. Acad. Sci. USA, 89, 1281, 10.1073/pnas.89.4.1281 Rumble, 1997, Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products, J. Clin. Invest., 99, 1016, 10.1172/JCI119229 Sage, 1991, Extracellular proteins that modulate cell–matrix interactions. SPARC, tenascin and thrombospondin, J. Biol. Chem., 266, 14831, 10.1016/S0021-9258(18)98545-5 Schmidt, 1961, Enzymatic determination of glucose and fructose simultaneously, Klin. Woch., 39, 1244, 10.1007/BF01506150 Simonsen, 1991, Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks, Clin. Sci., 80, 119, 10.1042/cs0800119 Soulis, 1996, The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment, Kidney Int., 50, 627, 10.1038/ki.1996.358 Tremble, 1993, SPARC, a secreted protein associated with morphogenesis and tissue remodelling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway, J. Cell. Biol., 121, 1433, 10.1083/jcb.121.6.1433 Vranes, 1999, Cellular mechanisms of diabetic vascular hypertrophy, Microvasc. Res., 57, 8, 10.1006/mvre.1998.2107 Wrana, 1991, Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen, Eur. J. Biochem., 197, 519, 10.1111/j.1432-1033.1991.tb15940.x Wu, 1997, Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system, J. Am. Soc. Nephrol., 8, 1374, 10.1681/ASN.V891373